Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PAM | P19021 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27726717 | 0.96 | TSHR (0.40) | TSHRMAPTPAMLMNAKDM4E | |
| SCHEMBL94759 | 0.91 | TSHR (0.48) | TSHRALDH1A1PGDHTTCYP2C9 | |
| SCHEMBL27558150 | 0.89 | MAPT (0.53) | TSHRMAPTPAMLMNAKDM4E | |
| SCHEMBL27805190 | 0.89 | MAPT (0.53) | TSHRMAPTPAMLMNAKDM4E | |
| SCHEMBL65559 | 0.89 | MAPT (0.53) | TSHRMAPTPAMLMNAKDM4E | |
| SCHEMBL29761219 | 0.89 | MAPT (0.53) | TSHRMAPTPAMLMNAKDM4E | |
| SCHEMBL27625179 | 0.89 | TSHR (0.46) | TSHRALDH1A1PGDHTTCYP2C9 | |
| SCHEMBL7035397 | 0.89 | TSHR (0.46) | TSHRALDH1A1PGDHTTCYP2C9 | |
| SCHEMBL27814847 | 0.88 | MAPT (0.43) | TSHRMAPTPAMLMNAKDM4E | |
| SCHEMBL11021553 | 0.88 | MAPT (0.51) | TSHRMAPTPAMLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105517997-A | Tetrahydrofuran derivatives and their use as plasticizers | BASF SE | 2016-04-20 | — | — | CN | disclosed |
| US-20110105443-A1 | SALTS OF MEMANTINE AND COX-INHIBITORS AND THEIR CRYSTAL FORM IN THE TREATMENT OF PAIN | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-05-05 | — | — | US | disclosed |
| EP-2098500-A1 | Salts of menantine and cox-inhibitors and their crystal form in the treatment of pain | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105443-A1 | SALTS OF MEMANTINE AND COX-INHIBITORS AND THEIR CRYSTAL FORM IN THE TREATMENT OF PAIN | OPRK1, GRIN2A, HTR2A | TSHR 4171/4885MAPT 99/4885PAM 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.